Nav1.8 inhibitors hold significant economic value and exhibit promising development trends in the global analgesics market. In 2022, the global market size for analgesic drugs reached approximately USD 91.14 billion, and it is projected to approach USD 90 billion by 2028. In China, the analgesics market was valued at approximately RMB 122.6 billion, with the expectation that China will become the largest and fastest-growing pain treatment market worldwide over the next decade. As a novel class o

Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected in the range between approximately $5.30 and $5.35 per share of common stock, expected in the third quarter of 2025 THB335 demonstrated 85% serum tryptase reduction with an encouraging safety profile in an additional Phase 1 cohort evaluating 100mg dose with new drug product capsule formulation Company initiating a sale process of THB335 June

77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 Data further support barzolvolimab clinical benefit to patients with CSU June 14, 2025 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of t

June 11, 2025 -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with stero

– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ORR in Ph 1 patients with R/R NUP98r AML – June 12, 2025 -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today ann

The fibroblast growth factor receptor (FGFR) family consists of transmembrane receptor tyrosine kinases that regulate a broad range of biological processes, including embryonic development, wound healing, and angiogenesis. Upon binding of FGFs (fibroblast growth factors) to their corresponding FGFRs, downstream signaling pathways—such as RAS-RAF-MAPK, PI3K-AKT/mTOR, STATs, and PLCγ/PKC—are activated, orchestrating cellular proliferation, survival, migration, and differentiation. In oncology, abe

The year 2024 marked an unprecedented boom in the field of antibody-drug conjugates (ADCs). With multiple innovative drugs advancing smoothly from Phase III clinical trials to regulatory review and market approval, the outlook for cancer treatment has become increasingly promising. These breakthrough ADCs have not only demonstrated remarkable efficacy and safety profiles but have also provided more personalized and precise therapeutic options for patients with various types of cancer. Whether ta

At the forefront of cancer treatment, scientists are continually exploring new targets and therapeutic strategies to address this global health challenge. B7-H3 (CD276), a type I transmembrane glycoprotein, has garnered significant attention due to its overexpression in a wide range of human cancers. Initially believed to function as a T-cell costimulatory molecule, B7-H3 has since been found to possess complex immunomodulatory properties, capable of both promoting and suppressing immune respons

– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma – June 05, 2025 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation

June 04, 2025 -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. (“Cook MyoSite”) to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-F